Literature DB >> 2158514

IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis.

D Jablons1, E Bolton, S Mertins, M Rubin, P Pizzo, S A Rosenberg, M T Lotze.   

Abstract

We performed functional assays on polymorphonuclear (PMN) leukocytes from 21 patients with advanced cancers, before, during, and after IL-2 administration. Of these, 19 were treated with high dose bolus IL-2 infusions (10(5) U/kg every 8 h) and 2 patients received low dose continuous infusions of IL-2 (250 U/kg/h). Five of six patients studied after IL-2 therapy had a decrease in their PMN chemotactic response to FMLP after bolus IL-2 (mean 8 doses) or, after the 4th day of continuous infusion IL-2 (pre-IL-2 values of 82% +/- 17% to 45% +/- 1% post-IL-2, p2 less than 0.004) compared with normal control values. In 8 of 10 patients studied, PMN capacity to oxidize intracellular dichlorofluorescein dye, an indirect measurement of O2- production in response to PMA stimulation, decreased after IL-2 administration (pre-IL-2 mean dichlorofluorescein oxidation (by channel number) 243 +/- 128 vs 3-day post-IL-2 87 +/- 86, p2 less than 0.02). Furthermore, a marked decrease in Fc gamma R III (Leu-11, CD16) expression was observed in 12/13 patients' PMN studied after IL-2 therapy (mean percent of PMN population with positive FcR expression was 81.1 +/- 15.4% pre-IL-2 which decreased to 56.0 +/- 30.5% post-IL-2, p2 less than 0.001). Other PMN surface markers (My4, My7, ICAM-1, LFA1, LFA3, Mac1) did not change significantly. PMN-mediated antibody-dependent cellular cytotoxicity did not change after IL-2 therapy (only 4/15 patients demonstrated more than 50% reduction in antibody-dependent cellular cytotoxicity). PMN phagocytosis of Staphylococcus aureus was also not significantly altered by IL-2 administration in six patients studied (pre-IL-2, 99 +/- 17% vs 111 +/- 28% post-IL-2, p2 greater than 0.2). We conclude that the systemic administration of IL-2 by intermittent or continuous administration is associated with marked changes in PMN function and cell surface receptor expression. These alterations may contribute to the apparent increased susceptibility to bacterial infection observed in these patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158514

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Effect of culture media on lymphokine-activated killer effector phenotype and lytic capacity.

Authors:  D M Finkelstein; R G Miller
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  On-chip evaluation of neutrophil activation and neutrophil-endothelial cell interaction during neutrophil chemotaxis.

Authors:  Donghyuk Kim; Christy L Haynes
Journal:  Anal Chem       Date:  2013-10-28       Impact factor: 6.986

3.  Neutrophil chemotaxis within a competing gradient of chemoattractants.

Authors:  Donghyuk Kim; Christy L Haynes
Journal:  Anal Chem       Date:  2012-06-28       Impact factor: 6.986

Review 4.  Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.

Authors:  Melissa G Lechner; Sarah M Russell; Rikki S Bass; Alan L Epstein
Journal:  Immunotherapy       Date:  2011-11       Impact factor: 4.196

Review 5.  The immunobiological effects of interleukin-2 in vivo.

Authors:  R A Janssen; N H Mulder; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

6.  Systemic administration of interleukin-2 inhibits inflammatory neutrophil migration: role of nitric oxide.

Authors:  Susana E Moreno; José C Alves-Filho; Giuliana Bertozi; Tais M Alfaya; Jacques Thèze; Sergio H Ferreira; Bernardo Boris Vargaftig
Journal:  Br J Pharmacol       Date:  2006-07-24       Impact factor: 8.739

7.  Totally implanted catheters to reduce catheter-related infections in patients receiving interleukin-2: a 2-year experience.

Authors:  B Escudier; J L Lethiec; E Angevin; A Andremont; M F Cosset-Delaigue; S Antoun; B Leclercq; G Nitenberg
Journal:  Support Care Cancer       Date:  1995-09       Impact factor: 3.603

Review 8.  Clinical toxicity of interleukin-2.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

9.  Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.

Authors:  S H Goey; A M Eggermont; C J Punt; R Slingerland; J W Gratama; R Oosterom; R Oskam; R L Bolhuis; G Stoter
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.